The drugs don’t work (and other mental health myths)
Our attitudes to mental health are changing but much of the stigma that surrounds conditions such as schizophrenia remains – along with some enduring and […]
Our attitudes to mental health are changing but much of the stigma that surrounds conditions such as schizophrenia remains – along with some enduring and […]
Sosei Heptares has taken another of its partnered G protein-coupled receptor (GPCR) programmes into mid-stage clinical trials, earning a $30 million milestone payment from Neurocrine […]
Teva’s long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company’s […]
BioXcel Therapeutics has claimed its first product approval, getting a green light from the FDA for Igalmi as a treatment for agitation in people with […]
Exclusive: Technology developed for new type of contraceptive pill could be applied to other medicines New technology that allows for daily medications to instead be […]
For any patients–but especially those with neurodevelopmental illnesses such as schizophrenia–have a consistent ‘medical home’ is vital for continuity of care. However, having consistent access […]
AbbVie returned the rights to the drugs to Sosei Heptares earlier this year. Now Neurocrine Biosciences has agreed to pay the Japanese drug company $100 […]
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in […]
Diagnoses for the disorder have soared in the past decade, driven in part by a loophole in regulations. A new study shows the impact has […]
Diagnoses for the disorder have soared in the past decade, driven in part by a loophole in regulations. A new study shows the impact has […]
Diagnoses for the disorder have soared in the past decade, driven in part by a loophole in regulations. A new study shows the impact has […]
At least 21 percent of nursing home residents are on antipsychotic drugs, a Times investigation found.
At least 21 percent of nursing home residents are on antipsychotic drugs, a Times investigation found.
Shots: The approval is based on a P-III study that evaluates Invega hafyera (q6mos., twice-yearly injectable) vs Invega trinza in 702 adults in a ratio […]
One of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit Janssen is trumpeting a new version of […]
Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders in particular represent a trial area with significantly high drop-out rates […]
The FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but it could still face a big challenge […]
Alkermes antipsychotic drug Lybalvi now has FDA approval. Though the field of neuropsychiatric drugs is crowded with generic medications, Alkermes believes Lybalvi, designed to mitigate […]
Shots: The BTD is based on P-II 1346.9 clinical trial, which demonstrated that BI 425809 improved cognition in adult patients with schizophrenia Moreover, the company […]
Shots: The NDA submission is based on P-III studies (SERENITY I & II) assessing BXCL501 (120 & 180mcg doses) vs PBO for the acute treatment […]
Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion […]
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a […]
Mitochondria destruction can help in Cancer Treatment Human cells require structures known as mitochondria for the generation of energy for their biochemical activities. Researchers at […]
Novartis is to buy neuroscience drugs firm Cadent Therapeutics in a deal worth up to $770 million. The big Swiss pharma already has a presence […]
Lundbeck has axed a phase 2 trial of a schizophrenia drug, saying that the study was unlikely to meet its efficacy target. The company said […]
Shots: The company discontinues P-II proof POC study of Lu AF11167 in patients with schizophrenia, who are experiencing persistent negative symptoms (NCT03793712). The P-II study […]
Copyright © 2024 | WordPress Theme by MH Themes